J Cardiovasc Dev Dis . Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review

[tetano]

J Cardiovasc Dev Dis


. 2021 Feb 12;8(2):18.
doi: 10.3390/jcdd8020018.
Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review


Fotios Barkas ¹ , Chrysoula-Paraskevi Styla ¹ , Aris Bechlioulis ² , Haralampos Milionis ¹ , Evangelos Liberopoulos ¹



Affiliations

• PMID: 33673216
• DOI: 10.3390/jcdd8020018

Free article

Abstract

Background: Although remdesivir treatment is widely used during the pandemic coronavirus disease 2019 (COVID-19), there is scarce evidence regarding its cardiac side effects.
Case presentation: We report the case of a 36-year-old male hospitalized due to severe COVID-19 symptoms. He presented with a 10-day history of fever (up to 39.7 ?C), productive cough, hemoptysis, fatigue, myalgias and hypoxemia. The patient received supplemental oxygen, dexamethasone, remdesivir and empirical antibiotic treatment according to protocol. Asymptomatic sinus bradycardia developed on hospital day 3 (namely, heart rate 39/min compared to 92/min on admission). Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work-up and echocardiographic examination. The patient's rhythm restored to normal 9 days after the discontinuation of remdesivir.
Conclusions: Considering the frequent use of remdesivir in patients with COVID-19, physicians should be aware of this possible adverse event.

Keywords: COVID-19; SARS-CoV-2; arrhythmia; bradycardia; remdesivir.